A patient with a scalp condition and benign skin tumor experienced hair loss and did not improve with treatment, choosing not to have surgery despite a small cancer risk.
The conversation discusses the use of TRT, dutasteride, minoxidil, and potentially RU58841 for hair loss. Concerns about the risk of developing Cutisverticisgyrata with minoxidil and TRT are raised.
User noticed tiny dots on their head after using 0.5% dutasteride and 8% minoxidil, which others identified as developing hair follicles. Encouragement was given to continue the treatment.
The conversation is about a user starting a hair loss treatment with Dutasteride, Minoxidil, and RU58841, hoping to prevent baldness. Other users comment on the user's current hair condition and the intensity of the chosen treatment.
PP405 is discussed as a potential adjunct therapy for hair loss, with skepticism about its effectiveness and trial results. Users mention combining it with finasteride and minoxidil for better results, while others debate the root causes of hair loss and the limitations of current treatments.
Pelage plans to conduct two Phase 3 trials for PP405, a new hair loss treatment, which may take about a year to complete. Users discuss various hair loss treatments, including pyrilutamide, minoxidil, finasteride, and clascoterone, with some expressing impatience over the lengthy trial process compared to faster drug approvals like the COVID vaccine.